News | August 19, 2025
Pfizer’s sickle cell disease candidate fails Phase III trial
Inclacumab was generally well tolerated in THRIVE-131
Inclacumab was generally well tolerated in THRIVE-131
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Pfizer's decision is based on the totality of clinical data
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
The National Sickle Cell Anaemia Elimination Mission was launched on 1st July 2023 at Shahdol, Madhya Pradesh
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Subscribe To Our Newsletter & Stay Updated
